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List of abbreviations: 
AUC Area under the curve 
BMI Body mass index 
BP Blood pressure 
CCM Corneal confocal microscopy 
CNFL Corneal nerve fibre length 
DNSS Diabetic neuropathy symptom score 
DR Diabetic retinopathy 
FLV Focal loss volume 
GCC Ganglion cell complex thickness 
GLV Global loss volume 
HDL High-density lipoprotein 
LDL Low-density lipoprotein 
NDS Neuropathy disability score 
NPDR Non-proliferative diabetic retinopathy 
PDR Proliferative retinopathy 
Peroneal nerve CV Peroneal nerve conduction velocity 
QST Quantitative sensory testing 
RNFL Retinal nerve fibre layer 
ROC Receiver operating characteristic curves 
Urine ACR Urine albumin-creatinine ratio 
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Abstract 
Aims 
To investigate the role of ophthalmic imaging markers – namely retinal thickness measures 
and corneal nerve morphology – in predicting four-year development and worsening of 
diabetic retinopathy (DR) in type 1 diabetes (T1DM). 
Methods 
126 eyes of 126 participants with T1DM were examined at baseline and after four years. 
Diabetic retinopathy (DR) was graded using the Early Treatment Diabetic Retinopathy Study 
scale. HbA1c, nephropathy, neuropathy, cardiovascular factors, and retinal thickness using 
optical coherence tomography (OCT) and corneal nerve fiber length (CNFL) using corneal 
confocal microscopy at baseline were assessed by univariate and step-wise multiple logistic 
regression, and their diagnostic capabilities for single and combined measures. 
Results 
Four-year development of DR was 19% (13 of 68 without DR at baseline). Worsening of DR 
was seen in 43% (25 of 58 with DR at baseline). When adjusted for potential confounders, a 
lower CNFL (AUC=0.637, p=0.040, 64% sensitivity and 64% specificity at 14.9 mm/mm2 cut-
off), higher triglycerides (AUC=0.669, p=0.012, 64% sensitivity, 62% specificity at 0.85 
mmol/L) and an elevated vibration threshold (AUC= 0.708, p=0.002, 96% sensitivity, 40% 
specificity at 3.55 Hertz) were significant predictors for four-year worsening of DR.  
Conclusions 
Reduced CNFL, elevated vibration perception threshold and higher triglycerides can predict 
future worsening of DR. 
Keywords 
Diabetic retinopathy, development, worsening, risk factors, retinal thickness, corneal nerve 
fibre length 
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Introduction 
Diabetic retinopathy (DR) is a major ocular complication of diabetes and a leading cause of 
vision loss in advanced stages1. All individuals with diabetes are at risk of developing DR1. 
Although there may be a loss of vision as a consequence of advanced DR, several 
subclinical visual functional changes occur even in the presence of good visual acuity 2, 3. 
Screening for factors which may help to predict the development and worsening of DR is 
therefore paramount to aid in early identification of those at high risk of more advanced DR 
with visual compromise. Prolonged duration of diabetes, poor glycemic control, higher blood 
pressure and dyslipidemia are some of the well-known risk factors for the development and 
worsening of DR.  
In recent years, research has increasingly focused on identifying early signs of neuroretinal 
degeneration in diabetes. Corneal confocal microscopy (CCM) has been ulilized4, 5 to 
demonstrate neuronal degeneration in participants with diabetes without clinical signs of DR 
and can differentiate participants with and without DR. In the present study, we examined 
the utility of optical coherence tomography (OCT)-derived retinal thickness parameters and 
CCM-derived corneal nerve fibre length (CNFL) and other conventional risk factors in 
predicting four-year development and worsening of DR in individuals with type 1 diabetes. 
Material and methods 
The study received ethics clearance from the Queensland University of Technology and 
Princess Alexandra Hospital Human Research Ethics Committees and was conducted 
according to the Tenets of Declaration of Helsinki as revised in 2008. Participants provided 
written informed consent prior to involvement. Individuals with type 1 diabetes were recruited 
from Princess Alexandra Hospital and from the broader Brisbane community. Concurrent 
assent was provided by both guardian and the participant for those aged between 14-18 
years. Participants who had their 18th birthday during their enrolment or follow up in the 
study were asked to re-assent to participate as an adult i.e. without parental consent. In this 
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instance the participants were asked to sign and date the consent document(s) for the study. 
The type of diabetes was ascertained from general practitioner reports. Information about 
the duration of diabetes was by self-report. 
One hundred and fifty seven participants with T1DM (age range 14 to 77 years) were 
examined at baseline; 28 participants did not attend follow-up, thus leaving a total of 129 
who presented for evaluation after 4 years.  The fundus photographs of three individuals 
were ungradable at follow-up due to cataract; therefore a total of 126 were examined for 
development and worsening of DR. (Fig 1) 
Participants underwent medical evaluation that included body mass index (BMI), systolic and 
diastolic blood pressure (BP), total cholesterol and triglyceride levels, and urine albumin-
creatinine ratio (ACR). 
Ophthalmic assessment 
Participants underwent visual acuity assessment, slit lamp biomicroscope examination, 
intraocular pressure measurement, and three-field fundus photography.  
Individuals with refractive error greater than ±6.00 D sphere, or astigmatism greater than 
±3.00 D cylinder were excluded. Individuals with cataract that prevented a good view of the 
posterior segment with fundus photography or optical coherence tomography (OCT), 
diagnosis or reasonable suspicion of glaucoma from optic nerve head appearance, 
intraocular pressure above 22 mmHg, or previously diagnosed neurological condition that 
might affect retinal nerve fibers (e.g., Parkinson’s disease 6 or multiple sclerosis 7) were 
excluded. 
Corneal confocal microscopy 
The cornea of the hand-dominant side was selected for confocal microscopic examination 
and anesthetized with a drop of 0.4% benoxinate hydrochloride (oxybuprocaine 
hydrochloride; Bausch & Lomb, New South Wales, Australia). The central region of the 
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cornea was examined using the Heidelberg Retina Tomograph III coupled with Rostock 
Cornea Module (Heidelberg Engineering, Heidelberg, Germany). Multiple images of the 
central corneal corneal subbasal nerve plexus (SNP) were acquired using section mode, and 
images showing in-focus nerves and not overlapping more than 20% were selected. A fully 
automated segmentation technique (ACCMetrics 8) was used to quantify the corneal nerve 
fiber length (CNFL). 
Retinopathy assessment 
Diabetic retinopathy was graded according to the Early Treatment Diabetic Retinopathy 
Study (ETDRS) scheme 9 by an ophthalmologist who was masked to the details of the 
participant. Development of DR was defined as newly developed DR after four years 
(ETDRS >10). Worsening was defined as worsening of DR (compared to grading at 
baseline) to any level.  
HbA1c of all participants was measured on the day of the ophthalmic examination. The eye 
on the side of the dominant hand was tested unless contraindicated by the above eligibility 
criteria, in which case, the eye on the non-dominant side was tested. 
Spectral domain OCT (RTVue, Model RT-100, ver.4.0, Fremont, CA, USA) was used to 
examine full retinal and inner retinal thickness. Full retinal thickness is measured along 12 
radial lines, each 6 mm long, centered at the fovea and averaged at three regions. The 
outermost region is the perifoveal zone that has an inner circle of diameter 3 mm and an 
outer circle of diameter 6 mm. The middle parafoveal zone has an inner circle of diameter of 
1 mm and an outer circle of diameter 3 mm. The innermost zone is that within the circle of 
diameter 1 mm that includes the fovea. RNFL thickness, which reportedly comprises axons 
of the ganglion cells, is measured along a circle of 3.45 mm diameter centered at the optic 
nerve head. The GCC is a composite of the inner plexiform layer, ganglion cell layer, and 
nerve fiber layer and is measured along 15 vertical lines and one horizontal line, covering a 
zone of 7 mm × 7 mm that is centered at 1 mm temporal to fovea.  
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The pattern-based GCC parameters, namely focal loss volume (GCC FLV) and global 
volume (GCC GLV), were also assessed. The GCC GLV reflects the average amount of 
GCC loss over the entire GCC map and is analogous in concept to the mean deviation (MD) 
of the visual fields. The GCC FLV detects focal loss after correcting for the overall sinking or 
the general depression of the topography of the GCC thickness map and is analogous to 
pattern standard deviation (PSD) measurement in visual fields. The overall thicknesses in 
the central zone, parafovea, perifovea, RNFL, and GCC were considered for analysis. 
Neuropathy assessment 
Study participants underwent neuropathy evaluation and were classified as ‘with or without 
neuropathy’, according to a modified neuropathy disability score (NDS). The NDS criterion 
involved neurological examination of three sensory modalities, namely vibration perception, 
sharp/blunt sensation, and temperature sensation. In addition, the ankle reflex testing was 
performed with a reflex hammer. A score of 0 is given for a normal response and 1 for an 
abnormal response for each individual test component. The ankle reflex was assessed using 
a reflex hammer, with the scores being 0 for normal, 1 for reinforcement, and 2 for absent. 
Each foot can have maximum score of 5, resulting in a total score of 10 for both feet. An 
NDS ≥3 is designated as neuropathy, with higher scores indicating more severe levels of 
neuropathy 10. 
Peroneal, tibial and sural nerve conduction velocities (CV) and amplitudes in the lower limb 
on the hand-dominant side were assessed as a part of neurophysiological examination using 
a Neuropack S1 EMG/Evoked Potential Measuring System (Nihon Kohden, Tokyo, Japan). 
Symptoms of the participants were assessed using a diabetic neuropathy symptom score 
(DNSS) questionnaire, and the outcome was recorded on a scale from 0 to 4, where a score 
greater than 0 indicates the presence of neuropathy 11. 
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Thresholds for heat, cold, heat pain, cold pain and vibration sensation were measured on the 
dorso-lateral aspect of the foot using the Medoc Quantitative Sensory Analyser, Model TSA-
II (Medoc Advanced Medical Systems, Ramat Yishai 30095, Israel).  
Statistical analysis 
The normality of data distribution was assessed using a Kolmogorov–Smirnov test. A Chi-
square test was applied for comparing proportions. A t-test and Mann-Whitney U test were 
utilized to test for significant overall differences among normally and non-normally distributed 
data, respectively. Statistical software for Social Sciences (SPSS) (SPSS Inc. Released 
2008. SPSS Statistics for Windows, Version 17.0. Chicago: SPSS Inc.) was used for 
analyses. A p-value of <0.05 was considered statistically significant. 
The relationship between DR status at follow-up and the clinical and ophthalmic baseline 
factors were explored using univariate and step-wise multiple logistic regression. Diagnostic 
performance was assessed by determining the area under the receiver operating 
characteristic curve (AUC), cut-off point, sensitivity and specificity for the predictive factors. 
Results 
Ninety four per cent of the study participants were Caucasians.  Thirteen participants (19%) 
with no DR at baseline had DR at follow-up (very mild non-proliferative diabetic retinopathy 
(NPDR) and mild NPDR only); there were no participants with proliferative diabetic 
retinopathy (PDR) at follow-up. Twenty five participants (43%) with DR at baseline showed 
worsening of DR; two (3%) progressed to PDR; and ten (17%) showed improvement of DR. 
At baseline, three participants had very mild NPDR, five had mild NPDR and two had high 
risk PDR. 
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‘Development of DR’ versus ‘no DR’ at follow-up 
Table 1 shows the baseline characteristics of those who did and did not develop DR at 
follow-up. Four-year development of DR was 19% (13 of 68 without DR at baseline had 
developed DR at follow-up). Eight were men and five were women in the ‘developed’ group. 
None of the ophthalmic variables were significantly different in the ‘developed’ group 
compared to ‘no DR’. The mean duration of diabetes was significantly higher (20 years 
versus 11 years, p=0.025) and the peroneal nerve conduction velocity (CV) was lower (47.5 
m/s versus 42.7 m/s, p=0.006) in the group that developed DR compared with those who did 
not develop DR at follow-up.  
Diabetes duration (p=0.954) and peroneal nerve CV (p=0.248) showed no significant 
association with the development of DR on logistic regression. 
‘Worsening of DR’ versus ‘stable or no DR’ at follow-up 
Table 2 compares the baseline characteristics of those who did and did not show worsening 
of DR at follow-up. Twenty five of 58 participants with DR at baseline (43%) showed 
worsening after four years. There were 15 men and 10 women in those who progressed. Of 
the 25 participants displaying worsening DR, seven (28%) progressed from very mild NPDR 
to mild NPDR; nine (36%) worsened from mild to moderate NPDR (1-step =16/25=64%); 
three progressed from very mild to moderate NPDR and one progressed from mild to severe 
NPDR (2-step =4/25=16%). Two progressed to PDR (3%). 
With regards to the ophthalmic variables, those who progressed had higher GCC FLV 
(p=0.007), and a lower CNFL (p=0.025) compared with those who had ‘stable retina or no 
DR’ on follow-up. 
 
Those who progressed had a higher HbA1c (p=0.026), longer duration of diabetes (p=0.011), 
higher body mass index (BMI) (p=0.002), higher urine albumin-creatinine ratio (ACR) 
(p=0.007), higher total cholesterol (p=0.006) and triglycerides (p=0.003), elevated vibration 
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perception threshold (p=0.026) and higher neuropathy disability score (NDS) (p=0.010) 
compared with those who had ‘stable DR or no DR’ at  follow-up. 
 
Factors predictive of DR worsening 
Table 4 shows the factors that predicted DR worsening. Lower CNFL (AUC=0.637, p=0.040, 
64% sensitivity and 64% specificity at 14.9 mm/mm2 cut-off), higher triglycerides 
(AUC=0.669, p=0.012, 64% sensitivity and 62% specificity at 0.85 mmol/L cut-off) and 
elevated vibration perception threshold (AUC=0.708, p=0.002, 96% sensitivity and 40% 
specificity at 3.55 Hertz cut-off) were significant predictors for four-year worsening of DR 
when adjusted for GCC FLV, HbA1c, duration of diabetes, BMI, urine ACR, serum lipids, 
vibration perception threshold and the NDS. 
 
Development or worsening of DR versus ‘stable or no DR’ at follow-up 
Table 3 shows the baseline ophthalmic and clinical variables for the combined group who 
showed development or worsening of DR. There were 41 women and 37 men in the group 
that remained stable at follow-up. 
None of the ophthalmic variables could differentiate those who showed development or 
worsening compared with those who had a stable retina at follow-up.   
 
Those who showed development or worsening of DR had a higher HbA1c (p=0.025), longer 
diabetes duration (p=0.022), higher triglycerides (p=0.025), higher BMI (p=0.015), higher 
ACR (p=0.032) and lower peroneal nerve CV (p=0.034) compared with those who remained 
stable or had no DR at follow-up. 
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Factors predictive of any change in DR  
Table 4 shows the factors predictive of change in retinopathy status defined as development 
or worsening of DR assessed using step-wise logistic regression. When adjusted for BMI, 
peroneal CV, ACR and serum triglycerides, higher HbA1c levels (p=0.017) and longer 
duration of diabetes (p<0.001) at baseline were significant predictors for development or 
worsening of pre-existing DR. HbA1c had an AUC of 0.638, with 66% sensitivity and 57% 
sensitivity for a cut-off 7.75%, while longer diabetes duration at baseline had an AUC of 
0.659, with a 95% sensitivity and 43% specificity for a cut-off  of 10.66 years. 
We also examined the predictive capability of combination of parameters for 
‘worsening’ alone and for ‘development or worsening’. The results are shown in Table 4. For 
predicting worsening of DR, the AUC was significant when combining CCMCNFL+ 
triglyceriides (AUC=0.667, 82% sensitivity and 52% specificity) and for 
CCMCNFL+QST+triglycerides (AUC=0.689, 85% sensitivity and 55% specificity). For 
development or worsening, the combined measures of HbA1c and diabetes duration 
demonstrated an AUC of 0.715, with 85% sensitivity and 57% specificity and were 
statistically significant. 
 
Discussion 
We specifically investigated the capability of OCT-derived retinal thickness parameters and 
CCM-derived CNFL in predicting the four-year development and worsening of DR in 
participants with T1DM.  
The four-year development of DR was 19% and worsening was 43%. Factors which 
independently predicted DR worsening were higher serum triglycerides, elevated vibration 
perception threshold and a lower CNFL. Risk factors for either DR development or 
worsening were longer duration of diabetes and a higher HbA1c. For the reason that our 
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study was not a population-based study, a more appropriate term for incidence would be 
‘development’ and that for progression would be ‘worsening’ of DR. 
In studies reporting follow-ups on DR comparable to our study (3-6 years) primarily 
conducted on cohorts with type 2 diabetes, the incidence of DR ranges from 8.07% to 58.5% 
12-30. Studies in type 1 diabetes of comparable follow-up duration are rare. 
DR incidence has been noted to vary with ethnicity 31, being higher among Latin Americans 
20, 21 and Asians, 13, 14, 16, 17compared with Caucasians and those of European descent 12, 18, 20, 
22, 23, 27, 28, 30, 32, 33. The above-mentioned studies encompass different ethnic groups. Above 
all, more recent studies report relatively lower incidences of DR compared to studies 
conducted more than two or three decades ago 12, 27, 28, 30. It is evident that the rates of 
incident DR appear to have reduced over a period of time and this could reflect changes in 
patient awareness and improvements diabetes care.  
We observed worsening to any level of severity of DR (43%) to be higher than that reported 
in previous studies; specifically, two-thirds of participants showed a 1-step progression and 
16% showed a 2-step progression. Literature reports on progression of DR are variable and 
vary with the eye considered for analysis (example worse eye). The BMES reported a 5-year 
progression of DR to be 25.9% while that in MVIP was 29%. In Asians, 1-step and 2-step 
progression were reported as 66% and 34.7%, respectively 16, 17 while in Europe, 1-step or 2-
step progression ranged from 13.5% to 38.9% 20, 21, 30.  A much higher DR progression is 
reported in the present study. 
We found that neither clinical nor ophthalmic variables are significant predictors of future 
development of DR, which may be attributed to the small number of patients who developed 
retinopathy (n=13). Both a higher GCC FLV and lower CNFL were significantly different in 
participants who showed worsening of DR than in those with stable or no DR. However, 
when adjusted for confounding factors, a lower CNFL, higher serum triglycerides and an 
elevated vibration perception threshold were significant predictors for worsening of DR.  
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The novel finding of this study is that CCM-derived CNFL is an independent predictive factor 
for future worsening of DR. Previous studies have documented diabetes-related neural 
degeneration in the cornea in patients with diabetes in relation to the presence 34-37 and 
severity 38 of diabetic peripheral neuropathy. CCM is capable of demonstrating neuronal 
regeneration after intervention such as pancreatic or kidney transplantation 39 and in 
predicting the future development of diabetic neuropathy.40 Interestingly, studies have shown 
that CCM-derived corneal nerve fibre length (CNFL), corneal nerve fibre density (CNFD) and 
corneal nerve branch density (CNBD) are reduced in patients with diabetes and no DR and 
are further compromised with severity of DR.41-43 CCM has been shown to detect 
neurodegeneration in the corneal nerves in the absence of clinical signs of DR 4, 5, 
suggesting that neuronal changes in diabetes precede detectable retinopathy. In this study, 
we demonstrate that CCM can predict future worsening of DR with fair diagnostic capability. 
Our study findings demonstrate that CCM is a novel ophthalmic marker that shows promise 
in predicting future worsening of DR in patients with diabetes, independent of the putative 
systemic risk factors. 
An elevated vibration perception threshold appeared to be a strong predictive factor for 
worsening of DR. In a cross-sectional study, Shen et al 44 demonstrated that a higher 
vibration perception threshold is associated with sight-threatening retinopathy. Our 
longitudinal study showed that an elevated vibration perception threshold is predictive of 
future worsening of predominantly mild to moderate stages of non-proliferative DR. This is 
yet another novel finding of our study. This suggests neurodegenerative changes in the 
distal leg may occur prior to visible vascular changes in DR. 
For development or worsening of DR, diabetes duration demonstrates 95% sensitivity and 
43% specificity for a cut-off of 11 years, while HbA1c demonstrates 66% sensitivity and 57% 
specificity for a cut-off of 7.7%. Both factors remained significant when adjusted for several 
potential confounders. The Diabetes Control and Complications Trial (DCCT)45 and the 
UKPDS28 have shown that diabetes duration is the strongest risk factor for DR. We show 
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that participants with T1DM and a HbA1c of ≥ 7.7% are at a greater risk of developing or 
progressing DR than those whose with HbA1c < 7.7%. A higher glycated hemoglobin level is 
associated with worsening of DR 45-47.  
We also observed that higher serum triglycerides is a risk factor for worsening of DR. 
Elevated serum triglyceride levels is a well-known risk factor for DR and diabetic macular 
edema 48-52. It has been hypothesized that higher levels of triglycerides may be associated 
with hyperviscosity 52, alterations to cell membrane transport and leakage of plasma with 
hard exudate formation. Alternately, hyperlipidemia can result in inflammation and 
endothelial dysfunction, with a break down in the blood-retinal barrier 53-56. Regression of DR 
has been demonstrated to be associated with a lowering of triglycerides 57, 58.  
There have been substantial changes in the diagnosis, monitoring and management of 
diabetes and its related complications over the past several years, and these approaches 
will continue to evolkve.59. Therefore, continuous evaluation is necessary. 
The strengths of our study include dilated 3-field photography and standard DR grading 
technique. The participants represented a well-phenotyped cohort.  
Our study limitations include the fact that the participants were volunteers from diabetic 
clinics; therefore, this was not a population-based study. We also assessed any 
development or worsening of DR in one eligible eye only (the worse eye), which may have 
resulted in higher proportions. Although er utilized 45 degree three-field dilated fundus 
photography for grading of DR, there may have been peripheral lesions, resulting in 
misdiagnosis or misclassification of DR stages. Three participants had cataractous haze that 
prevented a good view of the fundus. The drop-out rate in our study was 17%, which could 
have resulted in an underestimation of the development of PDR. Improvement in DR status 
occurred in 10 (17.2%) of the participants; however, because of the small numbers, we were 
unable to perform statistical analysis to explore the factors associated with this improvement. 
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In conclusion, we demonstrate the importance of ophthalmic imaging markers – specifically, 
OCT and CCM – in differentiating patients with T1DM who develop or show worsening of 
DR. In particular, reduced CNFL and elevated vibration perception threshold are capable of 
predicting future worsening of DR, while, longer duration of diabetes and a higher HbA1c 
levels are predictive factors for the future development or worsening of DR. Elevated serum 
triglycerides and HbA1c represent independent but modifiable risk factors for DR.  
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Figure legends: 
Fig 1. Baseline and follow-up status of study participants 
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Table 1.Baseline clinical and ophthalmic factors comparing those that did and did not develop DR after 4 years of 
follow up 
  At follow-up   
Baseline variables No DR (n=55) Incidence of DR(n=13)  
Ophthalmic variables Mean SD Mean SD p-values 
Central zone (incl. Fovea) (µm) 247 24 247 40 0.957 
Parafovea (µm) 318 16 314 18 0.485 
Perifovea (µm) 277 13 272 13 0.223 
RNFL thickness (µm) 109 11 105 12 0.243 
GCC thickness (µm) 100 8 98 6 0.325 
GCC FLV % 0.68 0.9 0.72 1.01 0.873 
GCC GLV % 3.11 3.88 3.79 3.95 0.575 
CCMCNFL mm per mm2 16.8 4.8 19.0 5.8 0.168 
Clinical variables           
Age 45.2 16.3 46.4 14.2 0.820 
HbA1c (% NGSP) 7.6 1.1 8.1 1.3 0.200 
Diabetes duration  (years) 11.5 12.2 20.2 12.3 0.025 
Cigarettes per day 15.0 14.7 12.2 9.0 0.667 
Alcohol units per week 6.7 9.9 8.5 7.5 0.612 
BP resting systolic (mm Hg) 125.0 17.2 123.5 14.8 0.786 
BP resting diastolic (mm Hg) 76.0 8.6 74.2 9.1 0.495 
BMI (kg/m
2
) 25.5 4.0 26.4 4.4 0.499 
Urine ACR (mg/mmol) 0.8 1.0 0.6 0.4 0.531 
Total cholesterol(mmol/L) 4.6 0.8 4.4 0.9 0.554 
HDL Cholesterol (mmol/L) 1.6 0.4 1.4 0.4 0.142 
Triglycerides (mmol/L) 0.9 0.4 0.9 0.3 0.840 
LDL Cholesterol (mmol/L) 2.6 0.7 2.6 0.8 0.879 
DNSS 0.3 0.6 0.4 0.5 0.664 
QST cold sensation threshold average (° C) 27.6 4.4 26.2 5.6 0.358 
QST warm sensation threshold average (° C) 37.9 4.1 40.4 5.1 0.064 
QST cold induced pain threshold average (° C) 11.1 9.6 9.4 11.4 0.586 
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QST warm induced pain threshold average (° C) 47.2 3.3 48.0 2.4 0.420 
QST vibration threshold average (Hz) 8.4 10.4 10.1 9.9 0.602 
Peroneal CV ankle to FH (m/s)  47.6 5.3 42.8 6.7 0.006 
NDS score 0.6 0.9 0.6 0.7 0.992 
Monofilament # of pts felt of 3  2.9 0.5 2.8 0.6 0.527 
BMI, Body mass index; BP, Blood pressure; CCM, Corneal confocal microscopy; CNFL, Corneal nerve fibre 
length;  
DNSS, Diabetic neuropathy symptom score;DR, Diabetic retinopathy; FLV, Focal loss volume;  
GCC, Ganglion cell complex thickness; GLV, Global loss volume; HDL, High-density lipoprotein; 
LDL, Low-density lipoprotein; NDS, Neuropathy disability; Peroneal CV, Peroneal nerve conduction velocity;  
QST, Quantitative sensory testing; RNFL, Retinal nerve fibre layer; Urine ACR, Urine albumin-creatinine ratio; 
Significant p-values in bold 
 
 
 
 
 
 
 
 
 
Table 2. Baseline clinical and ophthalmic factors in individuals with DR at baseline; a comparison of those that 
showed worsening of DR versus those with no change (‘stable or no DR’) 
 
  At follow-up   
Baseline parameters No change (n=78) DR Progression (n=25)   
ophthalmic variables Mean SD Mean SD p-values 
Central zone (incl. fovea) (µm) 246 25 252 27 0.259 
Parafovea (µm) 315 18 311 16 0.349 
Perifovea (µm) 276 15 275 10 0.864 
RNFL thickness (µm) 109 12 104 15 0.118 
GCC thickness (µm) 100 10 97 8 0.187 
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GCC FLV % 0.93 1.31 2.04 2.76 0.007 
GCC GLV % 3.67 4.58 4.92 4.53 0.238 
CCMCNFL mm per mm2 17.1 5.4 14.3 5.9 0.025 
Clinical variables           
Age 47.7 15.8 52.2 13.0 0.202 
HbA1c (% NGSP) 7.7 1.2 8.3 1.0 0.026 
Diabetes duration  (years) 17.7 15.3 26.1 9.4 0.011 
Cigarettes per day 14.7 12.7 12.4 13.0 0.595 
Alcohol units per week 6.9 8.6 9.3 10.3 0.307 
BP resting systolic (mmHg) 125.9 15.9 127.2 17.2 0.722 
BP resting diastolic (mmHg) 76.4 8.9 75.8 8.6 0.745 
BMI (kg/m
2
) 26.1 4.4 29.6 6.1 0.002 
Urine alb/creat ratio (mg/mmol) 0.8 1.0 14.3 42.2 0.007 
Total cholesterol(mmol/L) 4.6 0.9 5.2 1.2 0.006 
HDL Cholesterol (mmol/L) 1.6 0.5 1.6 0.6 0.888 
Triglycerides (mmol/L) 0.9 0.4 1.3 1.0 0.003 
LDL Cholesterol (mmol/L) 2.6 0.7 2.9 1.2 0.063 
DNSS 0.4 0.7 0.5 0.8 0.417 
QST cold sensation threshold average (° C) 26.6 5.6 25.5 5.9 0.417 
QST warm sensation threshold average (° C) 38.5 4.1 39.7 4.6 0.207 
QST cold induced pain threshold average (° C) 10.4 9.7 10.6 8.8 0.895 
QST warm induced pain threshold average (° C) 47.3 3.2 47.6 3.4 0.693 
QST vibration threshold average (Hz) 12.0 15.8 20.3 16.4 0.026 
Peroneal CV ankle to FH (m/s)  45.5 7.0 42.8 3.3 0.069 
NDS score 1.0 1.6 2.1 2.4 0.010 
Monofilament # of pts felt of 3  2.7 0.7 2.7 0.8 0.933 
 
BMI, Body mass index; BP, Blood pressure; CCM, Corneal confocal microscopy; CNFL, Corneal nerve fibre 
length;  
DNSS, Diabetic neuropathy symptom score; DR, Diabetic retinopathy; FLV, Focal loss volume;  
GCC, Ganglion cell complex thickness; GLV, Global loss volume; HDL, High-density lipoprotein; 
LDL, Low-density lipoprotein; NDS, Neuropathy disability;  Peroneal CV, Peroneal nerve conduction velocity;  
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QST, Quantitative sensory testing; RNFL, Retinal nerve fibre layer;  
Urine ACR, Urine albumin-creatinine ratio; 
Significant p-values in bold 
 
 
 
 
 
Table 3. Clinical and ophthalmic factors in the group that showed either incidence or progression of DR versus 
those with no DR/stable retina 
 
Baseline  variables No Change (n=78) 
Incidence OR 
Progression (n=38) 
 
Ophthalmic variables Mean SD Mean SD p-values 
Central zone (incl. fovea) (µm) 246 25 250 32 0.367 
Parafovea (µm) 315 18 312 17 0.443 
Perifovea (µm) 276 15 274 11 0.601 
RNFL thickness (µm) 109 12 104 14 0.087 
GCC thickness (µm) 100 10 98 7 0.152 
GCC FLV % 0.93 1.31 1.59 2.38 0.057 
GCC GLV % 3.67 4.58 4.53 4.32 0.336 
CCMCNFL mm per mm2 17.1 5.4 15.9 6.2 0.266 
Clinical variables           
Age 47.7 15.8 50.2 13.5 0.405 
HbA1c (% NGSP) 7.7 1.2 8.2 1.1 0.025 
Diabetes duration  (years) 17.7 15.3 24.1 10.7 0.022 
cigarettes per day 14.7 12.7 12.4 11.7 0.522 
alcohol units per week 6.9 8.6 9.1 9.4 0.288 
BP resting systolic (mmHg) 125.9 15.9 126.0 16.3 0.984 
BP resting diastolic (mmHg) 76.4 8.9 75.2 8.7 0.489 
BMI (kg/m2) 26.1 4.4 28.5 5.7 0.015 
Urine alb/creat ratio (mg/mmol) 0.8 1.0 9.5 34.4 0.032 
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Total cholesterol(mmol/L) 4.6 0.9 4.9 1.1 0.060 
HDL Cholesterol (mmol/L) 1.6 0.5 1.6 0.5 0.564 
Triglycerides (mmol/L) 0.9 0.4 1.2 0.8 0.025 
LDL Cholesterol (mmol/L) 2.6 0.7 2.8 1.1 0.132 
DNSS 0.4 0.7 0.5 0.7 0.522 
QST cold sensation threshold average (° C) 26.6 5.6 25.8 5.8 0.463 
QST warm sensation threshold average (° C) 38.5 4.1 39.9 4.8 0.088 
QST cold induced pain threshold average (° C) 10.4 9.7 10.2 9.7 0.942 
QST warm induced pain threshold average (° C) 47.3 3.2 47.8 3.1 0.487 
QST vibration threshold average (Hz) 12.0 15.8 16.8 15.1 0.123 
Peroneal CV ankle to FH (m/s)  45.5 7.0 42.8 4.7 0.034 
NDS score 1.0 1.6 1.6 2.1 0.103 
Monofilament # of pts felt of 3  2.7 0.7 2.7 0.8 0.830 
 
BMI, Body mass index; BP, Blood pressure; CCM, Corneal confocal microscopy; CNFL, Corneal nerve fibre 
length;  
DNSS, Diabetic neuropathy symptom score;DR, Diabetic retinopathy; FLV, Focal loss volume;  
GCC, Ganglion cell complex thickness;  GLV, Global loss volume; HDL, High-density lipoprotein; 
LDL, Low-density lipoprotein; NDS, Neuropathy disability; Peroneal CV, Peroneal nerve conduction velocity;  
QST, Quantitative sensory testing;RNFL, Retinal nerve fibre layer;  
Urine ACR, Urine albumin-creatinine ratio; 
Significant p-values in bold 
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Table 4. Predictive factors and their diagnostic capability for detecting DR progression alone and for either 
incidence or progression 
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AUC, Area under the curve; CCM, Corneal confocal microscopy; CNFL, Corneal nerve fibre length;  
DR, Diabetic retinopathy; QST, Quantitative sensory testing; BMI, body mass index; ACR, albumin-creatinine 
ratio; GCC FLV, ganglion cell complex focal loss volume; 
NDS, neuropathy disability score. 
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Figure 1 
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The study highlights the role of ophthalmological imaging technique namely, 
Corneal Confocal Microscropy (CCM) as a potential marker in predicting the 
future incidence of clinical signs of diabetic retinopathy (DR). The CCM could 
be of value in terms of identifying early neurodegenerative changes in the 
cornea in individuals with diabetes in predicting future incidence of DR. 
